STARRY BIO

A Rising Global Player for Osteoarthritis

2026. 6.

STARRY BIO

Investing Opportunity in Osteoarthritis(OA)

Highlights

- **Knee Osteoarthritis(OA) asset** : currently **Phase 3 dosing completed across 1,066 patients** in the US, **July 2024**
- **US Phase 3, Topline Data** : to be published **July, 2026**
- **Final US FDA Approval** : hopefully expected **"2027"**
- **Positive clinical outcomes(3,707patients in Korea)** : VAS(pain), 1.5X~2.0 greater reduction & IKDC(function), ~2.0X greater improvement compared to placebo
- **Secure Greater China & US rights for commercialization** : vision to be an innovative global biopharma company

Global Osteoarthritis Therapeutics Market



https://www.databridgemarketresearch.com/ko/reports/global-osteoarthritis-therapeutics-market

To be the first standardized CGT and New Standard of Care for Knee OA

(1) **We expect to be the first CGT for Knee OA** : The first standardized CGT for OA. Current treatments are NSAID, hyaluronic acid injections, physical therapy and the surgery

(2) **Stem Cell Treatments exhibit inconsistent efficacy** : Widely performed as premium pre-joint replacement treatments but its efficacy is highly dependent on hospital, clinician and patient

(3) **"Game-Changer" as new Standard of Care for Knee OA** : "Off-the-shelf" product and standardized treatment protocol : Will validate prior positive clinical outcomes in Korea(3,707 patients), positive VAS(1.5X ~ 2X greater pain reduction) and IKDC(2X greater functional improvement) compared to placebo

What is US Phase 3 Asset?

Novel Gene-Modified Cell Therapy for Osteoarthritis; It helps M2 macrophages restore balance in the articular tissue, which improves symptoms and helps repair cartilage



Prior Positive Clinical Outcomes in Korea

3,707 patients have received injections in South Korea the efficacy lasts over 3 years. VAS(pain reduction) is ~1.5X~2.0 greater pain reduction & IKDC(functional improvement) is ~2X greater functional improvement than placebo

Changes of IKDC Score from baseline



Changes of 100mm VAS Score from baseline

*Between treatment group: two-sample t –test or rank sum test, p -value<0.05;
**Within group ; statistically significant difference from baseline, p -value<0.05

Patients: 1Y 159 patients (TG-C group; n=78 vs. Placebo group; n=81)
2Y 112 patients(TG-C group; n=59 vs. Placebo group; n=53) / 3Y 99 patients(I TG-C group; n=54 vs. Placebo group; n=45) for FAS(Full Analysis Set)
Statistical Analysis: Linear mixed model
IKDC (International Knee Documentation Committee): Symptom, sports activity and function
100 mm VAS (Visual Analogue Scale): 0 being no pain and 100 being intolerable pain

Positive Clinical Results in US clinical trial

Topline data will be released around July, 2026.
The final US FDA Approval is expected around 2027.







* P-value<0.05 with in TG-C administrated group
Note 1) VAS: Visual Analog Scale
Note 2) IKDC: International Knee Documentation Committee
Note 3) OMERACT-OARSI: Outcome Measures in Rheumatology

Why NOW?

(1) **Right Timing before the valuation surges** : Secure Greater China and US market rights before this OA Asset valuation surges and competition becomes severe with the US FDA approval

(2) **Licensor's current financial situation, allowing favorable terms** : Original developer(licensor)'s current financial pressure might allow for favorable licensing terms and acquisition of Greater China & US rights

(3) **Recent precedent(Arvelle – SK Biopharm) exits** : XCOPRI of SK Biopharm was out-licensed to Arvelle 9 months before US approval, allowing both parties to capture values and establish "win-win".

Why StarryBio?

(1) **Ideal Vehicle for acquiring Greater China & US rights** : HQ in Seoul with close proximity & connection to licensor and neutral HQ to acquire rights and establish operations in Greater China & US both

(2) **Investment Opportunities for Global & Chinese investors** : Friendly cross-border fundraising environment and ability to enjoy the market potentials and returns of two key biopharma markets(US & China)

(3) **Flexible & Multiple Investors Exit Options** : IPO at Nasdaq, HKEx, Kosdaq or acquisition by major biopharma company.

(4) **Experienced Management Team** : Consists of seasoned IP & healthcare executives to secure favorable licensing agreement and to execute business plan for the delivery of return/exits for investors

Business Plans for StarryBio

Securing Greater China & US rights before US Approval

- Completing Licensing Agreement for the Greater China and US right either in sequence or parallel, depending on funding situation
- Initiating RA/Clinical development process in Greater China market for product market authorization
- Establish Operations in Korea, Greater China and US
- Product Launching and commercial excellence preparation for the US market after US right acquisition

Revenue Generation first in US then in Greater China upon market approval

- Revenue generation in the US
- Obtain regulatory approvals in Greater China markets(China, HK, TW)
- Establish GMP facility in China for production cost reduction

Pro Forma Revenue in the Greater China

- **Early Revenue in HK & Taiwan and Sharp Revenue Growth in China**

Year	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041
HK	0.0	0.0	0.0	4.0	9.5	15.0	18.8	22.3	25.3	29.3	33.5	37.0	38.5	40.3	41.5	43.3
Taiwan	0.0	0.0	0.0	6.8	17.1	30.0	39.3	52.8	59.1	72.3	88.8	100.5	116.9	117.3	116.65	119.5
China	0.0	0.0	0.0	0.0	21.3	42.5	77.5	120.0	162.5	225.0	295.0	365.0	420.0	475.0	525.0	575.0
Total	0.0	0.0	0.0	10.8	47.9	87.5	135.5	195.0	246.8	326.5	417.3	502.5	575.4	632.5	683.2	737.7



P&L Forecast in Greater China

- **Expects to generate revenue in 2029 and be profitable in 2030**

Year	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041
Revenue	0.0	0.0	0.0	10.8	47.9	87.5	135.5	195.0	246.8	326.5	417.3	502.5	575.4	632.5	683.2	737.7
Costs	1.6	3.8	6.7	13.3	23.9	43.8	67.8	97.5	123.4	163.3	208.6	251.2	287.7	316.3	341.6	368.9
Profits	-1.6	-3.8	-6.7	-2.5	23.9	43.8	67.8	97.5	123.4	163.3	208.6	251.2	287.7	316.3	341.6	368.9



Pro Forma Revenue in US

- **Expects to breakeven in the US by 2029 and over USD 4Bn sales in 2034 with steady growth to reach peak revenue of up to USD 6Bn by 2042**

Year	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042
Revenue	0	70	250	650	1100	1800	2500	3300	4000	4300	4700	5100	5300	5500	5700	5900	6100
Cost	50	100	150	300	450	600	850	1000	1200	1300	1400	1500	1600	1700	1800	1900	2000
Profit	-50	-30	100	350	650	1200	1650	2300	2800	3000	3300	3600	3700	3800	3900	4000	4100



Exit Scenarios for Investors

- **Expected ROI of 3X~10X over 3 to 5 years**

- 2027 : US FDA Approval(Early Secondary / revaluation)
- 2028-2029 : TW & HK Approvals(Strategic Equity placement / M&A)
- 2030+ : Multi-region Commercialization(IPO / M&A)
- 2030-2031 : Market Approval in China (IPO / M&A)



(1) Funding Round for Greater China right

Target Investment Amount : up to USD91.5M

Use of Fund

- First In-Licensing upfront to Licensor : USD 2M ~ 5M
- Second In-Licensing upfront after US Approval : USD 5M ~ 10M
- HK / Taiwan Bridging / Small Trial : USD 2M ~ 5M
- China Bridging / Confirmatory Trial : USD 10M ~ 25M
- Regulatory / Consulting (China, HK, Taiwan) : USD 4M ~ 8M
- Operating Cost of StarryBio (2-3 years in KR/CN) : USD 4.5M ~ 6.5M
- Quality Assurance, Audit, Insurance : USD 1M ~ 2M
- Establishing GMP Facility in China : USD 20M ~ 35M

(1) By Tranche : Funding Round for GC Right

Tranche 1 : USD10M contingent on LOI for Licensing with Licensor

- Upfront payment to Licensor
- Operations (focusing clinical development) set up for Greater China

Tranche 2 : USD30M upon U.S. FDA approval

- Milestone payment to Licensor & Establishment of China Subsidiary
- Launch of China clinical program & possible Bridging Trial in HK/Taiwan

Tranche 3 : USD30M for China IND and for TW&HK BLA

- Clinical development and regulatory consultation in China, TW&HK
- Product Launching & Manufacturing readiness in China

Tranche 4 : USD21.5M for BLA and product launch in China

- Product Launching and Commercial Excellence(Sales & Marketing, Medical affairs & distribution)

(2) Funding Round for US right

Target Investment : about USD300M up to USD700M for commercialization

- Upfront for US market acquisition and commercialization preparation until reaching to the BEP in 3 years

Use of Fund

- US Market in-Licensing 1st upfront to Licensor : USD 50M ~ 100M
- In-Licensing 2nd upfront after final US Approval : USD 150M ~ 300M
- US Marketing Preparation for 2-3 years : USD 25M ~ 50M
- US Operating Cost of StarryBio (2-3 years) : USD 25M ~ 50M
- Setting Up OA Asset GMP Facility in the US : USD 50M ~ 100M

(2) By Tranche : Funding Round for US Right

Tranche 1 : USD75M - 150M to acquire US right(pre-FDA Approval)

- 1st upfront to Licensor before the final FDA approval(preferably, refundable)
- Preparation of US sales/marketing team

Tranche 2 : USD150M - 300M (upon U.S. FDA approval)

- 2nd upfront to Licensor after the final FDA approval
- Preparation to the level of ready to generate revenue across the US market

Tranche 3 : USD25M – 50M (Post-Approval Clinical/Regulatory activities)

- Post-approval regulatory procedures
- Tracking safety after approval and preparation of further OA indications

Tranche 4 : USD50M – 100M for securing US manufacturing facilities in the US

- Further expanding clinics across the US market
- Preparation of manufacturing facilities in the US

Syndication-Ready Investment Opportunity

Currently forming an investor syndicate for the acquisition of Greater China and US market rights for commercialization in both markets

Multiple Investors Ready to Co-Invest

- Several regional healthcare-focused investors (from HK, Taiwan, China & SG) have expressed soft commitments to co-invest

Fast Closing Once lead term Sheet

- Soft commitments already enough for targeted amount, enabling rapid closing upon confirmation of lead investment

Attractive Lead Investor Position

- Lead investor will have flexibility in valuation negotiation and participation rights in future global expansion rounds.

Investor Protection Mechanism

(1) **Contingent Investment Structure** : Investment may be conditional upon successful licensing and the funds releasing tied to milestones

(2) **Escrow / Holdback Mechanism** : investment may be held in escrow until license agreement is executed.

(3) **Risk-Sharing / Option Agreements** : investors may have structure a buy-back or exit option

Thank You!

For more information, please contact us at nst@djin.co.kr